Compare FEIM & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | CATX |
|---|---|---|
| Founded | 1961 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 497.9M |
| IPO Year | 1994 | 2018 |
| Metric | FEIM | CATX |
|---|---|---|
| Price | $68.32 | $3.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $51.50 | $12.11 |
| AVG Volume (30 Days) | 143.8K | ★ 1.3M |
| Earning Date | 03-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | N/A |
| P/E Ratio | $176.63 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $18.63 | $1.96 |
| 52 Week High | $76.07 | $6.16 |
| Indicator | FEIM | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 28.04 |
| Support Level | $43.53 | $1.98 |
| Resistance Level | $76.07 | $3.80 |
| Average True Range (ATR) | 5.11 | 0.25 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 62.83 | 0.38 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.